Depression nursing care: major depressive disorder reference

Major depressive disorder (MDD) is defined by at least two weeks of depressed mood or loss of interest (anhedonia) — one of these two must be present — plus four additional symptoms from the DSM-5 criteria list, totaling five or more. It affects approximately 7% of the US population annually, with the highest prevalence in adults aged 18–29 and a female-to-male ratio of roughly 2:1. MDD accounts for approximately 10% of NCLEX psychiatric questions and is the most common reason for psychiatric hospitalization.

This reference covers the full clinical picture: DSM-5 criteria, psychiatric assessment tools, suicide risk assessment, nursing interventions, antidepressant pharmacology, serotonin syndrome, ECT, and psychiatric emergencies. Use it alongside the pharmacology nursing guide and drug classifications reference for integrated pharmacology coverage.

DSM-5 diagnostic criteria: SIGECAPS quick reference

Five of nine symptoms required, present for at least two consecutive weeks, representing a change from baseline. At least one symptom must be depressed mood or anhedonia (loss of interest or pleasure). Symptoms must cause clinically significant distress or functional impairment and must not be attributable to a substance or medical condition.

Core anchor symptoms (one required): Depressed mood most of the day, nearly every day (may appear as irritability in adolescents) — OR — markedly diminished interest or pleasure in almost all activities most of the day.

Exclusions: Symptoms cannot be due to another medical condition (hypothyroidism, anemia, neurological disorder), bereavement alone (though grief can coexist), a manic or hypomanic episode, or direct physiological effects of a substance.

Psychiatric assessment tools

PHQ-9 (Patient Health Questionnaire-9)

The PHQ-9 is a nine-item patient self-report tool that maps directly to the DSM-5 criteria. Each item is scored 0–3 (not at all / several days / more than half the days / nearly every day). Total score: 0–27.

• Minimal (0–4): No treatment indicated, monitor
• Mild (5–9): Watchful waiting; consider supportive counseling
• Moderate (10–14): Antidepressant or psychotherapy; repeat PHQ-9 in 2–4 weeks
• Moderately severe (15–19): Antidepressant plus psychotherapy
• Severe (20–27): Antidepressant, psychotherapy, and consider psychiatric referral

Item 9 (suicidal ideation) must always be reviewed independently, regardless of total score. A “several days” response triggers immediate safety assessment.

Hamilton Depression Rating Scale (HAM-D)

The HAM-D is a clinician-administered structured interview — not patient self-report. The standard version has 17 items assessing mood, guilt, suicidal ideation, sleep patterns, work/activities, psychomotor changes, anxiety, somatic symptoms, and insight. Score interpretation: 0–7 (no depression), 8–17 (mild), 18–24 (moderate), 25+ (severe). The HAM-D is used primarily in clinical research and to measure treatment response over time. Nurses in research settings administer it; in standard clinical practice, it is used by psychiatrists and advanced practice providers.

Beck Depression Inventory (BDI)

The BDI is a 21-item patient self-report tool measuring cognitive, affective, and somatic symptoms. Like the PHQ-9, it screens and tracks severity over time. The BDI is widely used in outpatient mental health settings. Scores range 0–63: minimal (0–13), mild (14–19), moderate (20–28), severe (29–63).

Clinical selection guide: PHQ-9 is the standard primary care and inpatient screen (fast, validated, free). HAM-D is the gold standard for research and clinician-rated assessment. BDI is useful in outpatient psychiatric follow-up to track treatment response.

Safety assessment: suicide risk

Suicide risk assessment is the highest-priority nursing intervention in MDD. Assess every patient at admission, with any change in mental status, and before each discharge.

Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is the most widely used standardized suicide risk tool, developed by Columbia University and now mandated by the FDA for clinical trials. It assesses two domains:

Ideation scale (1–5, escalating severity):

1. Wish to be dead
2. Non-specific suicidal thoughts
3. Active ideation without plan/intent
4. Active ideation with some intent (no plan)
5. Active ideation with plan and intent

Behavior scale: Actual attempts, interrupted attempts, aborted attempts, preparatory behaviors.

A score of 4 or 5 on the ideation scale, or any behavior scale event, requires immediate psychiatric evaluation and likely inpatient placement.

SAD PERSONS mnemonic (risk factor screening)

Protective factors (reduce risk): reasons for living, children at home, religious beliefs, social support, fear of death or pain, active treatment engagement, problem-solving ability.

Level of care decision

• Outpatient: Passive ideation only (wish to be dead, no active plan); adequate social support; reliable follow-up within 1–2 days; no prior high-lethality attempts; agrees to safety plan
• Intensive outpatient / partial hospitalization: Active ideation without intent; some risk factors; needs daily monitoring
• Inpatient psychiatric: Active ideation with plan or intent; recent attempt; psychotic features; inadequate social support; unable to contract for safety; high-lethality plan; substance intoxication

Nursing interventions

Therapeutic communication

The therapeutic relationship is the foundation of psychiatric nursing care. Key principles:

Open-ended questions: “Tell me what’s been going on for you” opens conversation. Closed yes/no questions (“Are you sad?”) shut it down.

Active listening: Maintain eye contact, lean forward, use minimal encouragers (“go on,” “tell me more”), reflect content and feeling: “It sounds like you’ve been feeling completely alone.”

Avoid false reassurance: “Everything will be fine” and “I’m sure it will get better” are harmful — they minimize the patient’s experience and erode trust. Say instead: “I care about what happens to you” or “I’m here with you right now.”

Avoid toxic positivity: “You have so much to live for” is dismissive. “What’s kept you going up to this point?” invites reflection without judgment.

Do not challenge hopelessness directly: Arguing that “life is worth living” rarely helps. Explore the meaning behind hopelessness: “When you say there’s no point, what does that feel like?”

Safety planning (preferred over no-harm contracts)

Safety planning — collaboratively developed with the patient — is the evidence-based standard. A safety plan includes:

1. Warning signs to watch for (personal triggers, thoughts, behaviors)
2. Internal coping strategies (distraction, grounding techniques)
3. Social contacts who provide distraction (friends, family — not crisis-specific)
4. People to ask for help (trusted support network)
5. Professionals and agencies to contact in crisis (therapist, psychiatrist, 988 Lifeline)
6. Means restriction: making the environment safer (removing firearms, medications, sharps)

Critical note on no-harm contracts: Despite widespread use (79% of inpatient units), no-suicide contracts have no empirical evidence of effectiveness and are considered contraindicated by current psychiatric literature. Published case reports document patients completing suicide or self-harm after signing contracts. No-harm contracts should not replace proper safety planning. When used at all, they should be viewed as one element of rapport-building — not a clinical safeguard.

Environmental safety

• Assess room on admission: remove sharps, ligatures (belts, shoelaces, phone cords), excess medications
• 1:1 observation for high-acuity patients; 15-minute checks at minimum for moderate risk
• Ensure bathroom access is supervised for high-risk patients
• Document all safety checks with times and patient status

Milieu therapy

Milieu therapy uses the structured inpatient environment itself as a therapeutic tool. Components include:

• Structure and routine: Scheduled mealtimes, group therapy, activity groups, and sleep times reduce chaos and provide predictability
• Peer support: Patients learn from each other’s coping strategies in group settings
• Nurse presence: Consistent therapeutic engagement — not just task-based interaction
• Goal-setting: Daily achievable goals (attend morning group, eat breakfast, walk to the dayroom) build self-efficacy
• Boundaries and expectations: Clear behavioral expectations create safety and reduce anxiety

Physical care

• Sleep hygiene: Maintain consistent wake and sleep times; reduce caffeine; limit screen exposure; encourage physical activity during the day
• Nutrition: Assess appetite and weight trends; offer preferred foods; small frequent meals for anorexia; monitor weight weekly
• Activity: Even brief walks (10–20 minutes) show measurable antidepressant effect. Start low-intensity, increase gradually
• ADL support: Provide direction without doing everything — encourage autonomy. Severely depressed patients may need step-by-step prompting for basic hygiene

Pharmacology: antidepressant classes

Universal antidepressant principles:

• Therapeutic lag: 4–6 weeks for full clinical effect (mood improvement); patients may notice sleep and appetite improvement in 1–2 weeks
• FDA black box warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults ages 18–24 during the first weeks of treatment — monitor closely and increase visit frequency
• Advise patients not to stop abruptly — discontinuation syndrome with SSRIs/SNRIs can mimic flu (FINISH mnemonic: Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal)

MAOI-tyramine interaction: the mechanism

MAOIs irreversibly inhibit the enzyme monoamine oxidase in the gut wall and liver, which normally degrades dietary tyramine before it enters systemic circulation. When tyramine is absorbed intact, it enters adrenergic nerve terminals and displaces norepinephrine from storage granules, causing a massive, acute release of norepinephrine. The result: severe, potentially life-threatening hypertensive crisis — severe headache (occipital), diaphoresis, palpitations, BP >180/120.

Foods to avoid with MAOIs: aged cheeses (highest risk), cured/fermented meats (pepperoni, salami), sauerkraut, soy sauce, tap beer, overripe or dried fruit, fava beans, liver. Fresh foods and processed foods with controlled sodium are generally safe.

MAOI washout periods:

• Stop MAOI → start SSRI: wait 14 days (time for new MAO enzyme synthesis)
• Stop fluoxetine → start MAOI: wait 5 weeks (fluoxetine’s long half-life)
• Stop other SSRIs → start MAOI: wait 14 days

TCA overdose: the 3 C’s

TCA overdose is one of the most dangerous medication-related emergencies in psychiatry. The 3 C’s:

• Coma — anticholinergic CNS effects cause rapid loss of consciousness
• Convulsions — seizures from sodium channel blockade
• Cardiac arrhythmias — the most lethal manifestation

Mechanism of cardiac toxicity: TCAs block fast voltage-gated sodium channels in myocardial cells, slowing phase 0 of the action potential. This widens the QRS complex on EKG. QRS >100 ms predicts seizures; QRS >160 ms predicts ventricular arrhythmias.

Treatment — sodium bicarbonate: Sodium bicarbonate (1 mEq/kg IV bolus) is the antidote for TCA cardiac toxicity. It works by: (1) providing a sodium load that competes with TCA channel blockade, and (2) alkalinizing the serum (target pH 7.5–7.55), which reduces TCA binding affinity to sodium channels and increases protein binding of TCAs, reducing the free active fraction. Target: narrow the QRS and maintain pH 7.5–7.55. Avoid physostigmine (contraindicated — can precipitate asystole) and avoid Type 1A/1C antiarrhythmics.

Serotonin syndrome

Serotonin syndrome results from excess serotonergic activity at central and peripheral receptors. Most cases involve combining two or more serotonergic agents (SSRI + MAOI, SSRI + tramadol, SSRI + linezolid, SSRI + triptans) or a large dose increase.

The diagnostic triad

1. Mental status changes: Agitation, anxiety, confusion, restlessness
2. Autonomic instability: Hyperthermia, tachycardia, diaphoresis, hypertension, diarrhea
3. Neuromuscular abnormalities: Tremor, myoclonus, hyperreflexia, clonus (especially lower extremities)

Onset: Within 24 hours of medication change (often within 6 hours) — this distinguishes it from NMS.

Hunter criteria (diagnostic standard)

Serotonergic agent exposure PLUS one of:

• Spontaneous clonus
• Inducible clonus + agitation or diaphoresis
• Ocular clonus + agitation or diaphoresis
• Tremor + hyperreflexia
• Hypertonia + temperature >38°C + ocular or inducible clonus

The Hunter criteria are more sensitive (84%) and specific (97%) than the older Sternbach criteria.

Serotonin syndrome vs. neuroleptic malignant syndrome

Key differentiator on NCLEX: Hyperreflexia and clonus = serotonin syndrome. Severe “lead pipe” rigidity + antipsychotic exposure = NMS.

Management

1. Discontinue all serotonergic agents immediately
2. Supportive care: IV fluids, cooling measures for hyperthermia, oxygen
3. Benzodiazepines for agitation and seizures
4. Cyproheptadine (a serotonin antagonist, 4–8 mg PO/NG) — first-line pharmacologic treatment
5. ICU admission for severe cases

Electroconvulsive therapy (ECT)

ECT delivers a controlled electrical stimulus to the brain under general anesthesia, inducing a brief generalized seizure. It is the most effective acute treatment for severe depression, with response rates of 60–80% — superior to any single antidepressant.

Indications

• Severe, refractory MDD unresponsive to multiple antidepressant trials
• Psychotic depression (delusions, hallucinations accompanying MDD)
• Catatonia
• Suicidal emergency requiring rapid response (ECT works within days; antidepressants take weeks)
• Severe medical compromise that prohibits antidepressants (e.g., pregnancy, cardiac disease)
• Patient preference with prior ECT response

How ECT works

The exact mechanism is not fully established, but the induced seizure is necessary — subconvulsive stimuli do not produce antidepressant effects. Proposed mechanisms include modulation of neurotransmitter systems (serotonin, dopamine, GABA), normalization of HPA axis dysfunction, and neuroplasticity effects (BDNF upregulation). A typical course is 6–12 treatments, given 3×/week. Benefit often appears within 1 week of starting.

Nursing role: pre-procedure

• Obtain informed consent (ECT requires explicit written consent; patient must understand risks including memory effects)
• NPO after midnight (general anesthesia)
• Remove jewelry, dentures, glasses, hearing aids
• Baseline vital signs and neurological assessment
• Confirm IV access; administer prescribed premedications (glycopyrrolate to reduce oral secretions; muscle relaxant — succinylcholine; short-acting anesthetic — methohexital or propofol)
• Brief seizure monitoring equipment: EEG leads placed on scalp, pulse oximetry, cardiac monitoring

Nursing role: intra-procedure

• Monitor vital signs continuously
• Observe and document seizure duration (EEG monitoring — a successful therapeutic seizure lasts 25–60 seconds)
• Monitor oxygen saturation; provide supplemental O2 before and after stimulus
• Assist anesthesia team

Nursing role: post-procedure (recovery)

• Monitor airway, breathing, circulation until patient is fully awake
• Reorient the patient — post-ictal confusion is expected and resolves in minutes to 30 minutes
• Assess vital signs every 5 minutes until stable
• Monitor for headache, nausea, and muscle aches (common, manage with PRN medications)
• Reassure patient and family that confusion is temporary
• Memory side effects: Retrograde amnesia (difficulty recalling events before ECT) and anterograde amnesia (forming new memories) are common and usually temporary. Most patients recover memory over weeks to months after the ECT course ends. Bilateral electrode placement produces more memory impairment than unilateral. Inform patients and families that memory effects are expected — this is the most distressing side effect and requires proactive counseling.

Psychiatric emergencies in MDD

Suicidal ideation with plan and intent (C-SSRS level 4–5)

Immediate intervention required. Do not leave the patient alone. Notify the physician/provider immediately. Initiate 1:1 observation. Remove access to means. Prepare for emergency psychiatric evaluation and likely inpatient admission. Document: ideation content, plan, means, intent, timeframe, and patient’s exact words.

Psychotic depression

MDD with psychotic features presents as delusions or hallucinations in the context of a depressive episode. Delusions are typically mood-congruent (themes of guilt, worthlessness, poverty, persecution, or somatic concerns like belief of having cancer or being “rotting inside”). Command hallucinations instructing the patient to harm self require immediate evaluation and very high level of observation. Treatment requires both an antidepressant and an antipsychotic — or ECT (first-line for severe psychotic depression).

Catatonia

Catatonia in the context of MDD presents as motor immobility (stupor), mutism, negativism (active resistance to instructions), posturing, rigidity, or echolalia/echopraxia. It is a medical emergency — patients cannot eat, drink, or communicate. Benzodiazepines (lorazepam) are first-line; ECT is highly effective when benzodiazepines fail. Nursing priorities: airway and nutrition (NG tube may be needed), prevent pressure injuries, monitor for aspiration, maintain hygiene.

Therapeutic communication: do’s and don’ts

NCLEX tips: 10 high-yield points

1. SIGECAPS = 5 of 9 DSM-5 criteria. Always remember: at least one symptom must be depressed mood OR anhedonia — neither alone qualifies a diagnosis without the other four symptoms.

2. C-SSRS levels 4 and 5 (ideation with intent; ideation with plan and intent) require immediate intervention — do not leave the patient alone, notify provider, initiate 1:1 observation.

3. MAOI + tyramine = hypertensive crisis. The mechanism: MAOIs block tyramine degradation in the gut → absorbed tyramine displaces norepinephrine from storage granules → massive NE release → severe hypertension. Headache (severe, occipital) is the classic presenting symptom.

4. TCA overdose: 3 C’s — Coma, Convulsions, Cardiac arrhythmias. QRS >100 ms on EKG predicts seizures; >160 ms predicts arrhythmia. Treatment: sodium bicarbonate IV (alkalinizes serum, reduces TCA binding to sodium channels). Avoid physostigmine and Type 1A antiarrhythmics.

5. Antidepressant black box warning: Increased suicidality in children, adolescents, and adults ages 18–24 during the first weeks of treatment. Monitor closely and increase visit frequency at treatment initiation. This does not apply to adults over 24 — older adults may actually have lower suicidality risk with antidepressants.

6. Therapeutic lag = 4–6 weeks for full antidepressant effect on mood. Sleep and appetite may improve in 1–2 weeks. Educate patients not to discontinue early due to perceived lack of effect.

7. Serotonin syndrome triad: Mental status changes + autonomic instability + neuromuscular abnormalities (hyperreflexia, clonus, myoclonus). Onset within hours of medication change. Treatment: stop all serotonergic agents, give cyproheptadine. Differentiator from NMS: hyperreflexia vs. lead-pipe rigidity; hours vs. days to onset.

8. ECT memory side effects: Temporary retrograde and anterograde amnesia are expected and usually resolve after the treatment course. This is the most distressing side effect — counsel patients and families proactively. Document baseline cognitive status before starting ECT.

9. Milieu therapy uses the structured therapeutic environment as treatment: routine, peer support, group activities, nurse presence, achievable daily goals. It is a nursing intervention — nurses are responsible for maintaining and facilitating the therapeutic milieu.

10. Priority nursing diagnosis for suicidal patient: Risk for self-directed violence (or: Risk for suicide) — this is always the priority nursing diagnosis when suicide risk is present. No other nursing diagnosis takes precedence over patient safety.

Related references

• Pharmacology nursing guide: drug classes and mechanisms
• Drug classifications nursing reference
• Nursing lab values cheat sheet — relevant for lithium levels (if used as augmentation), metabolic monitoring
• Sepsis nursing reference — for patients with comorbid medical illness and MDD

Clinical references: DSM-5 (APA); StatPearls — Major Depressive Disorder (Nursing), NCBI Bookshelf NBK570554, NBK568733; NCBI Bookshelf — Depressive Disorders NBK590047; Columbia Suicide Severity Rating Scale protocol (Columbia University); PMC — Serotonin Syndrome PMC3865832, PMC5713790; StatPearls — Tricyclic Antidepressant Toxicity NBK430931; Mcmyler & Pryjmachuk (2008), Do “no-suicide” contracts work?, Journal of Psychiatric and Mental Health Nursing; NIMH epidemiology data.